Richard Jackson
Psychiatry · Boca Raton, FLNPI 1508081993
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,638,559 of the $3,609,819 with a category attached, or 73.1%. 36 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 34.7% of the total. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,871 payments — averaging $932.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1.3M
- Alkermes, Inc.$618K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$322K
- Otsuka America Pharmaceutical, Inc.$315K
- Vanda Pharmaceuticals Inc.$240K
- E.r. Squibb & Sons, L.L.C.$210K
- plus $651K from 30 others
Across 168 payments — averaging $2826.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$121K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$90K
- Neurocrine Biosciences, Inc.$89K
- AbbVie$49K
- Teva Pharmaceuticals USA, Inc.$37K
- Boehringer Ingelheim$29K
- plus $60K from 6 others
What the payments were for
- Consulting fees$343,07110%
- Speaking & faculty fees$2,638,55973%
- Travel & lodging$530,12215%
- Food & beverage$98,0213%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,414,122
- ARISTADA$936,930
- AUSTEDO$767,027
- Austedo XR$375,606
- CAPLYTA$317,358
- Fanapt$237,781
- ARISTADA INITIO$214,484
- QELBREE$177,138
- ABILIFY MAINTENA$160,434
- REXULTI$151,378
- COBENFY$151,071
- ABILIFY ASIMTUFII$96,388
- UZEDY$85,692
- VRAYLAR$74,841
- Jornay PM 20mg capsules (Bottle of 100)$59,987
- LATUDA$56,866
- IGALMI$47,019
- Auvelity$42,703
- Azstarys$23,524
- Xelstrym$23,039
How this compares
$3,609,819 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 23 | $241,748 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,942 |
| LoxapineLoxapine Succinate | 12 | $1,285 |
| Olanzapine | 11 | $152 |
| Lorazepam | 15 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Loxapine | $1,254,092 | $243,03335 claims |
| Alkermes, Inc.Lybalvi | $618,373 | $18,94212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Boca Raton
- Mustafa PirzadaBoca Raton$122K
- Andrew CutlerLakewood Ranch$5.7M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.